Rare diseases
Investigational molecules
Locations
Back to Belgium16 clinical trials in Pelt, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.
BelgiumOrelabrutinib in Patients with Primary Progressive Multiple Sclerosis
BelgiumA study to compare the effectiveness and safety of subcutaneous frexalimab versus intravenous frexalimab in adults with multiple sclerosis
BelgiumStudy comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment
BelgiumStudy on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis
BelgiumStudy on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis
BelgiumStudy on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis
BelgiumStudy on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis
BelgiumStudy on the Effects of Obexelimab for Patients with Relapsing Multiple Sclerosis
BelgiumStudy on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis
BelgiumStudy on the Effects of a Higher Dose of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis
BelgiumStudy on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis
BelgiumThe busiest research cities in the country
What the registry says about research in the country
Extensive research focusing on relapsing forms of multiple sclerosis, evaluating novel therapeutic approaches and comparing treatment efficacies. Studies investigate various medications including frexalimab and remibrutinib against established treatments.
Several trials aim to assess reduction in relapse frequency and improvement in patient outcomes.
Dedicated research into primary progressive multiple sclerosis (PPMS) and secondary progressive forms, exploring innovative treatments and their impact on disease progression. Studies evaluate higher-dose protocols and long-term effectiveness.
Focus on developing treatments to delay disability progression and improve patient mobility.
Investigation of innovative treatment modalities including BTK inhibitors and combination therapies. Research includes assessment of brain remyelination and neurodegeneration markers.
Comprehensive evaluation of new therapeutic approaches using advanced imaging and clinical assessments.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
